Table 1.

Summary of drugs for the acute treatment of menstrual migraine. OLS indicates open-label study; RCT, randomized controlled trial.

Drug	Available Studies	Main Findings
Single drug
Frovatriptan	5 RCTs vs. other triptans [40,41,42]; 1 OLS	Early relief: superior to placebo, equivalent to other triptans Sustained relief: superior to almotriptan, rizatriptan, zolmitriptan Non-headache symptoms: effective on nausea and phonophobia, not on other symptoms Adverse events: comparable to placebo Other outcomes: higher patient satisfaction with frovatriptan compared with previous treatments
Sumatriptan	3 RCTs [33,34,35]	Early relief: superior to placebo Sustained relief: comparable to placebo Non-headache symptoms: effective on photophobia and phonophobia Adverse events: comparable to placebo
Naratriptan	1 RCT [37]	Early relief: superior to placebo Sustained relief: superior to placebo Non-headache symptoms: superior to placebo for all symptoms Adverse events: comparable to placebo Other outcomes: superior to placebo in ability to carry on daily activities and patient satisfaction
Zolmitriptan	1 RCT [38]	Early relief: superior to placebo Adverse events: comparable to placebo
Almotriptan	1 RCT [39]	Superior to placebo in pain-free status at 2 and 24 h; significant reduction in nausea and photophobia; adverse events comparable to placebo
Combination drugs
Sumatriptan + naproxen	5 RCTs [50,51,52]	Early relief: superior to placebo Sustained relief: superior to placebo, especially with comorbid dysmenorrhea Adverse events: comparable to placebo Other outcomes: patient satisfaction, productivity, quality of life
Frovatriptan + dexketoprofen	1 RCT [53]	Early relief: superior to frovatriptan alone Sustained relief: superior to frovatriptan alone Adverse events: comparable to frovatriptan alone